ITMCTR2023000056招募中1 期
Evaluation of the efficacy of Ruanjian Qingmai granules in the treatment of peripheral arterial disease after revascularization
Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 至 90(—)
- 性别
- All
入选标准
- •(1) Clinical data before undergoing revascularization meet the diagnostic criteria of PAD in the Guidelines for Diagnosis and Treatment of Lower Extremity Atherosclerotic Occlusive Disease 2016 compiled by the Vascular Surgery Group of the Surgery Branch of the Chinese Medical Association, as well as meet the diagnostic criteria of desmoplasia in the Diagnostic Efficacy Criteria for Chinese Medicine Internal Medicine Disease (ZY/T001.1-94) of the Chinese People's Republic of China Traditional Chinese Medicine Industry Standard; (2) 40 < age = 90 years old, gender is not limited; (3) have undergone lower limb revascularization within the last 6 months; (4) agree to participate in this clinical trial and voluntarily sign the informed consent.
排除标准
- •(1) patients with acute lower extremity ischemia scheduled for lower extremity revascularization and those with a history of major amputation; (2) patients with occlusion of the common femoral or above, femoro-iliac arteries, or occlusion of the arteries above the groin; (3) patients with inflammatory vascular diseases such as atherosclerotic occlusions of the non-lower extremity arteries such as multiple large arteritis, thrombo-occlusive vasculitis, and others; (4) patients who have had a pulmonary embolism in the last 3 months, a myocardial infarction, severe cardiac failure, transient ischemic attack or acute ischemic stroke and other ischemic events in the past 3 months; (5) allergy to RJQM; (6) the presence of severe hepatic or renal insufficiency, malignant tumors, mental anomalies, pregnancy, or preparation for pregnancy prior to randomization, and other patients considered by the investigator as unsuitable for participation in this study; and (7) those who have been involved in a clinical trial of other drugs in the past 6 months.
研究者
相似试验
尚未招募
1 期
Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenzainfluenzaITMCTR2000002885onghua Hospital Shanghai University of Traditional Chinese Medicine
尚未招募
1 期
A randomized controlled trial of Ruanjian Qingmai Granule in the treatment of peripheral arterial diseaseperipheral arterial diseaseITMCTR2200005580shanghai TCM-Integrated Hospital
招募中
不适用
Evaluation of the clinical efficacy of Qinghuatanshi Decoction in the treatment of Plasma cell mastitis during perioperative periodPlasma cell mastitisITMCTR2100005055Shuguang Hospital Affiliated to Shanghai University of traditional Chinese Medicine
已完成
不适用
Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial.ulcerative colitisJPRN-UMIN000019103The Jikei University Kashiwa Hospital68
尚未招募
4 期
Evaluation of the clinical efficacy of Guanxinning tablets in the treatment of patients with carotid atherosclerotic plaqueCarotid atherosclerotic plaque formationITMCTR2100005440Dongzhimen Hospital, Beijing University of Chinese Medicine
